BLOG

Fierce-Biotech

Boehringer boards B-cell depletion bandwagon, paying Cue $12M to line up autoimmune attack

Cue applied technology it initially tested in the treatment of cancers to the development of CUE-501. The idea is to make B cells appear as if they are infected with a virus such as cytomegalovirus or SARS-CoV-2.